June 11, 2008 - The court approved the settlement, entered the orders approving the plan of allocation, the motion for attorneys’ fees and expenses, and dismissed the action with prejudice.
February 20, 2008 - The court preliminarily approved the settlement.

February 11, 2008 - Parties filed a stipulation of settlement.

November 9, 2006 - The court ordered the complaint dismissed against another individual defendant.

May 17, 2006 - The court ordered the complaint dismissed against six individual defendants.

May 23, 2005 - The court ordered the complaint dismissed against four underwriter defendants.

July 12, 2004 - The lead plaintiffs filed a notice of voluntary dismissal of the claims arising from the December 12, 2001 offering of Transkaryotic Therapies Inc securities asserted in Counts I and II of the amended consolidated complaint.

May 26, 2004 - The court granted in part and denied in part the defendants' motions to dismiss.

September 17, 2003 - The defendants filed motions to dismiss.

July 7, 2003 - The lead plaintiffs filed an amended consolidated complaint on behalf of investors who purchased Transkaryotic Therapies Inc (NASDAQ: TKTX) common shares between January 4, 2001 and January 10, 2003. The lead plaintiffs allege that the defendants violated the Securities Exchange Act of 1934 by issuing false and misleading statements between January 4, 2001 and January 10, 2003.

April 9, 2003 - The lead plaintiffs and lead counsel were appointed and all cases were consolidated.

March 25, 2003 - Lead plaintiff motions were filed.

January 24, 2003 - An investor in shares of Transkaryotic Therapies Inc (NASDAQ: TKTX) filed a lawsuit in the U.S. District Court for the District of Massachusetts against Transkaryotic Therapies Inc over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements made between January 4, 2001 and January 14, 2003.

The complaint alleges that Transkaryotic Therapies Inc made misrepresentations and nondisclosures of material fact to the investing public concerning Transkaryotic Therapies Inc's prospects for FDA approval for the marketing of Transkaryotic Therapies Inc's Replagal enzyme therapy for the treatment of Fabry disease. Plaintiffs charge that Transkaryotic Therapies Inc knew by virtue of their ongoing communications with the FDA that the FDA considered Transkaryotic Therapies Inc's data on the primary pain reduction endpoint of Transkaryotic Therapies Inc's Phase II study to be uninterpretable, and further that the FDA considered that Transkaryotic Therapies Inc's cardiac and renal data did not support approval. According to testimony at the January 14, 2003 Advisory Committee hearing, in a letter dated December 22, 2000, the FDA had advised Transkaryotic Therapies Inc that the clinical study data (from the Phase II studies) had not provided substantial evidence of efficiency and fully detailed the facts leading to that conclusion. (The FDA's Center for Biologics Evaluation and Research) recommended that additional clinical studies be conducted.

On January 15, 2003, Transkaryotic Therapies Inc (NASDAQ: TKTX) stock closed at $6.49, more than 85% below its high.